Abstract
The use of existing drugs and the development of new ones for use in children have been subject to many pressures, scientific, economic, social and political. In the period from 1970 to 1990, huge progress was made in the management of many serious illnesses in children utilising drugs which to a large extent were unlicensed for use in this age group. Indeed survival for children with leukaemia increased from 10 % in 1970 to almost 80 % by 1990, using drugs which had not been formally evaluated for use in children and for which no licensing or marketing authorisation had been sought or given. This is currently greater than 90 % because of most children now being part of a clinical trial as part of their treatment regimen in the UK.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hull, D., Choonara, I., Sammons, H., Beresford, M. (2017). Medicines for Children. In: Craft, A., Dodd, K. (eds) From an Association to a Royal College. Springer, Cham. https://doi.org/10.1007/978-3-319-43582-4_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-43582-4_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43581-7
Online ISBN: 978-3-319-43582-4
eBook Packages: MedicineMedicine (R0)